GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
KR |
|
Marimekko Oyj
OTC:MKKOF
|
FI |
|
G
|
Gem Resources PLC
LSE:GEMR
|
UK |
Multiples-Based Value
The Multiples-Based Value of one GI Innovation Inc stock under the Base Case scenario is 104.2 KRW. Compared to the current market price of 12 170 KRW, GI Innovation Inc is Overvalued by 99%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
GI Innovation Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
G
|
GI Innovation Inc
KOSDAQ:358570
|
774.8B KRW | 2 291.7 | -14.9 | -17.4 | -16.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD | 6 | 87.3 | 14.5 | 20.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD | 5 | 23.9 | 13.9 | 13.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD | 5.9 | 20.5 | 12.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD | 9.2 | 27.9 | 20.9 | 21.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD | 5.6 | 17.9 | 13.4 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3 | 33.2 | 11.2 | 14 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |